<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="3-part\PMC7115636\results\search\disease\results.xml">
  <result pre="resource centre remains active. Abstract Background The impact of annual" exact="influenza" post="epidemics and prevailing strains varies worldwide and regional. The"/>
  <result pre="worldwide and regional. The majority of vaccines used contained two" exact="influenza" post="A strains and only one influenza B strain (trivalent"/>
  <result pre="vaccines used contained two influenza A strains and only one" exact="influenza" post="B strain (trivalent vaccine). Aim The aim of the"/>
  <result pre="The aim of the study was to compare laboratory confirmed" exact="influenza" post="B cases during three consecutive years with respect to"/>
  <result pre="retrieved from patient charts. Findings During the 2015/16 season, 75" exact="influenza" post="B cases were retrieved; 11 in 2016/17, and 274"/>
  <result pre="clustered similarly in 2017/2018 when compared to the previous two" exact="influenza" post="seasons. While the relative frequency of influenza B cases"/>
  <result pre="the previous two influenza seasons. While the relative frequency of" exact="influenza" post="B cases differed, the clinical symptoms remained similar. Conclusion"/>
  <result pre="recommendations for the use of tetravalent vaccines that contain two" exact="influenza" post="B strains (Yamagata and Victoria) in addition to the"/>
  <result pre="B strains (Yamagata and Victoria) in addition to the two" exact="influenza" post="A strains (H1N1 and H3N2) should be implemented in"/>
  <result pre="single stranded, negative sense RNA genome. First isolated in 1940," exact="influenza" post="B virus diverged into two lineages, Victoria and Yamagata,"/>
  <result pre="seals were observed, there is no known animal reservoir for" exact="influenza" post="B [4]. Thus, while influenza A infections can be"/>
  <result pre="no known animal reservoir for influenza B [4]. Thus, while" exact="influenza" post="A infections can be zoonotic, influenza B virus only"/>
  <result pre="B [4]. Thus, while influenza A infections can be zoonotic," exact="influenza" post="B virus only circulates in the human population. The"/>
  <result pre="the main contributing factors to the less frequent occurrence of" exact="influenza" post="B epidemics [6]. In 2017/18 influenza B predominance was"/>
  <result pre="less frequent occurrence of influenza B epidemics [6]. In 2017/18" exact="influenza" post="B predominance was reported in countries throughout the northern"/>
  <result pre="in countries throughout the northern hemisphere. It was the leading" exact="influenza" post="type in Europe and Canada [7], [8], [9] and"/>
  <result pre="[7], [8], [9] and the second most common type after" exact="influenza" post="A/H3N2 in the USA [10]. In Germany, after the"/>
  <result pre="fourth season of the 21st century with a dominance of" exact="influenza" post="B [11]. As the prevailing lineage of influenza B"/>
  <result pre="dominance of influenza B [11]. As the prevailing lineage of" exact="influenza" post="B changes frequently, the World Health Organization (WHO) recommended"/>
  <result pre="reduced in seasons in which the formulation of the trivalent" exact="influenza" post="vaccine does not match the circulating strain due to"/>
  <result pre="study was to analyze clinical and molecular features of laboratory-confirmed" exact="influenza" post="B cases during three consecutive seasons between 2015 and"/>
  <result pre="Texas, USA) according to the manufacturer’s instructions. The panel included" exact="influenza" post="viruses A and B, respiratory syncytial virus A and"/>
  <result pre="performed according to WHO guidance [20]. In cases of low" exact="influenza" post="B concentration an alternative protocol generating three instead of"/>
  <result pre="of &amp;lt; 0.05 was considered significant. 3 Results 3.1 Weekly detection of" exact="influenza" post="B cases Relative and absolute numbers of influenza types"/>
  <result pre="detection of influenza B cases Relative and absolute numbers of" exact="influenza" post="types detected between 2015 and 2018 are shown in"/>
  <result pre="supplementary Fig. S1. Table 1 Total and relative numbers of" exact="influenza" post="types per season. Season Influenza B A/H3N2 A/H1N1 Total"/>
  <result pre="20 (5.6) 66 (18.3) 360 Bold numbers represent the dominant" exact="influenza" post="type of the respective season. Fig. 1 Number of"/>
  <result pre="season. Fig. 1 Number of patients with laboratory-confirmed diagnosis of" exact="influenza" post="B per week (columns) for season 2015/16 (A) and"/>
  <result pre="Study population and clinical features A total of 360 laboratory-confirmed" exact="influenza" post="B cases were included in the study and were"/>
  <result pre="analysis was done to compare the clinical features of the" exact="influenza" post="B infections of the pediatric and adult patients with"/>
  <result pre="and fatal outcomes were observed. Fig. 2 Relative distribution of" exact="influenza" post="B cases by age. Season 2017/18 is represented by"/>
  <result pre="white bars. Table 2 Study population and clinical features of" exact="influenza" post="B infected cases. Analyzed categories are displayed on the"/>
  <result pre="Sufficient material for the phylogenetic lineage determination of the detected" exact="influenza" post="B viruses was available in 337 (93.6%) of the"/>
  <result pre="patients that had a fatal outcome within 30 days of the" exact="influenza" post="B detection (n = 27). Except for one strain of 2017,"/>
  <result pre="hemagglutinin (HA) nucleotide sequences of (A) Victoria- and (B) Yamagata-like" exact="influenza" post="B viruses. Trees were constructed based upon nucleic acid"/>
  <result pre="following characteristics: 15x○; 15x�?; 3x□, 1x■, 14x△. 4 Discussion The" exact="influenza" post="season of 2017/18 was dominated by the Yamagata-lineage of"/>
  <result pre="influenza season of 2017/18 was dominated by the Yamagata-lineage of" exact="influenza" post="B in Europe. In Germany, it was the largest"/>
  <result pre="[11]. Large scale epidemics or pandemics are usually caused by" exact="influenza" post="A. This is attributed mostly to the broader host"/>
  <result pre="the broader host range and faster rate of evolution of" exact="influenza" post="A [6]. Influenza B infections usually occur with a"/>
  <result pre="occur with a temporal delay towards the end of an" exact="influenza" post="A-dominated season [23]. The exceptional impact of influenza B"/>
  <result pre="of an influenza A-dominated season [23]. The exceptional impact of" exact="influenza" post="B infections in 2017/18 with regard to public health"/>
  <result pre="was therefore surprising. However, seasons with a high proportion of" exact="influenza" post="B infections occur infrequently. Specifically, in Germany, the mild"/>
  <result pre="and the severe season of 2015/16 have been dominated by" exact="influenza" post="B with a share of up to 78% of"/>
  <result pre="B with a share of up to 78% of all" exact="influenza" post="cases. The high severity of the season 2017/18 with"/>
  <result pre="be attributed to several factors. According to the ECDC, the" exact="influenza" post="season of 2017/18 started earlier than most of previous"/>
  <result pre="this is true for the epidemic phase of the two" exact="influenza" post="B heavy seasons in this study, the time frame"/>
  <result pre="Both the attack rate and the relative illness ratio of" exact="influenza" post="B are highest for children and decrease with age"/>
  <result pre="that might have contributed to a severe outcome of the" exact="influenza" post="disease, as it is known for example for cardiac"/>
  <result pre="general population. A third potential factor may be the circulating" exact="influenza" post="type. The Yamagata-lineage of influenza B was predominantly found"/>
  <result pre="factor may be the circulating influenza type. The Yamagata-lineage of" exact="influenza" post="B was predominantly found in the season of 2017/18."/>
  <result pre="reason for this might be the interplay between the circulating" exact="influenza" post="strains causing infections and the choice of the vaccine"/>
  <result pre="season of 2015/16 Influenza A/H1N1 pdm09 and the Victoria-lineage of" exact="influenza" post="B caused the majority of influenza infections. In 2016/17"/>
  <result pre="and the Victoria-lineage of influenza B caused the majority of" exact="influenza" post="infections. In 2016/17 influenza A/H3N2 was the main cause"/>
  <result pre="influenza B caused the majority of influenza infections. In 2016/17" exact="influenza" post="A/H3N2 was the main cause of flu disease. When"/>
  <result pre="the main cause of flu disease. When looking at the" exact="influenza" post="B component of the broadly used trivalent influenza vaccine"/>
  <result pre="at the influenza B component of the broadly used trivalent" exact="influenza" post="vaccine there was a switch from B/Phuket/3073/2013-like (Yamagata-lineage) to"/>
  <result pre="by recent epidemics or the current vaccine composition was the" exact="influenza" post="B Yamagata-lineage. An increased proportion of non-immune individuals in"/>
  <result pre="individuals [30], [31] but the contribution to the immunity against" exact="influenza" post="B is not well defined. Some degree of lineage"/>
  <result pre="of lineage cross-protection has been reported upon vaccination with trivalent" exact="influenza" post="virus vaccines. However, it seems to be limited to"/>
  <result pre="age groups and the vaccine efficacy is consistently superior for" exact="influenza" post="B strains belonging to the vaccine lineage [32], [33],"/>
  <result pre="the vaccinated patients were adults. However, a major improvement to" exact="influenza" post="disease burden may only be accomplished by extending vaccine"/>
  <result pre="recommendations for the use of tetravalent vaccines that contain two" exact="influenza" post="B strains (Yamagata and Victoria) in addition to the"/>
  <result pre="B strains (Yamagata and Victoria) in addition to the two" exact="influenza" post="A strains (H1N1 and H3N2) should be implemented in"/>
  <result pre="Germany as a result of the severity of the 2017/18" exact="influenza" post="season. Author contribution Study design: UGL Data collection: MH,"/>
  <result pre="work reported in this paper. References References 1BouvierN.M.PaleseP.The biology of" exact="influenza" post="virusesVaccine26Suppl 4200853 2CainiS.KronemanM.WiegersT.El Guerche-SéblainC.PagetJ.Clinical characteristics and severity of influenza"/>
  <result pre="of influenza virusesVaccine26Suppl 4200853 2CainiS.KronemanM.WiegersT.El Guerche-SéblainC.PagetJ.Clinical characteristics and severity of" exact="influenza" post="infections by virus type, subtype and lineage: a systematic"/>
  <result pre="literature reviewInfluenza Other Respir Viruses201878079229858537 3VijaykrishnaD.HolmesE.C.JosephU.The contrasting phylodynamics of human" exact="influenza" post="B virusesElife42015e05055 4BaileyE.S.ChoiJ.Y.FieldhouseJ.K.The continual threat of influenza virus infections"/>
  <result pre="phylodynamics of human influenza B virusesElife42015e05055 4BaileyE.S.ChoiJ.Y.FieldhouseJ.K.The continual threat of" exact="influenza" post="virus infections at the human-animal interface: what is new"/>
  <result pre="Med Public Health2018201819219830210800 5NobusawaE.SatoK.Comparison of the mutation rates of human" exact="influenza" post="A and B virusesJ Virol8020063675367816537638 6PetrovaV.N.RussellC.A.The evolution of seasonal"/>
  <result pre="influenza A and B virusesJ Virol8020063675367816537638 6PetrovaV.N.RussellC.A.The evolution of seasonal" exact="influenza" post="virusesNat Rev Microbiol162018476029081496 7MachadoA.KislayaI.NunesB.RodriguesA.P.GuiomarR.Moderate influenza vaccine effectiveness in a"/>
  <result pre="Virol8020063675367816537638 6PetrovaV.N.RussellC.A.The evolution of seasonal influenza virusesNat Rev Microbiol162018476029081496 7MachadoA.KislayaI.NunesB.RodriguesA.P.GuiomarR.Moderate" exact="influenza" post="vaccine effectiveness in a B mismatch season: Preliminary results"/>
  <result pre="the 2017/2018 season in PortugalPulmonology24201826026229903599 8SkowronskiD.M.ChambersC.de SerresG.Early season co-circulation of" exact="influenza" post="A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness,"/>
  <result pre="Influenza Reports.[German] last accessed 15.12.2018, &amp;lt;https://influenza.rki.de/Saisonbericht.aspx&amp;gt;. 12DolinR.The quadrivalent approach to" exact="influenza" post="vaccinationJ Infect Dis208201353954023847061 13SuptawiwatO.NinpanK.BoonarkartC.RuangrungK.AuewarakulP.Evolutionary dynamic of antigenic residues on"/>
  <result pre="influenza vaccinationJ Infect Dis208201353954023847061 13SuptawiwatO.NinpanK.BoonarkartC.RuangrungK.AuewarakulP.Evolutionary dynamic of antigenic residues on" exact="influenza" post="B hemagglutininVirology5022017849628024225 14LeeJ.BoutzD.R.ChromikovaV.Molecular-level analysis of the serum antibody repertoire"/>
  <result pre="serum antibody repertoire in young adults before and after seasonal" exact="influenza" post="vaccinationNat Med2220161456146427820605 15HiranoD.OhshimaN.Kubota-KoketsuR.Three types of broadly reacting antibodies against"/>
  <result pre="antibodies against Influenza B viruses induced by vaccination with seasonal" exact="influenza" post="virusesJ Immunol Res20182018725179329854845 16BelsheR.B.CoelinghK.AmbroseC.S.WooJ.C.WuX.Efficacy of live attenuated influenza vaccine"/>
  <result pre="with seasonal influenza virusesJ Immunol Res20182018725179329854845 16BelsheR.B.CoelinghK.AmbroseC.S.WooJ.C.WuX.Efficacy of live attenuated" exact="influenza" post="vaccine in children against influenza B viruses by lineage"/>
  <result pre="Res20182018725179329854845 16BelsheR.B.CoelinghK.AmbroseC.S.WooJ.C.WuX.Efficacy of live attenuated influenza vaccine in children against" exact="influenza" post="B viruses by lineage and antigenic similarityVaccine2820102149215620003926 17PanY.DeemM.W.Prediction of"/>
  <result pre="influenza B viruses by lineage and antigenic similarityVaccine2820102149215620003926 17PanY.DeemM.W.Prediction of" exact="influenza" post="B vaccine effectiveness from sequence dataVaccine3420164610461727473305 18RayG.T.LewisN.KleinN.P.Intra-season Waning of"/>
  <result pre="Influenza vaccine effectivenessClin Infect Dis2018 19van EldenL.J.NijhuisM.SchipperP.SchuurmanR.van LoonA.M.Simultaneous detection of" exact="influenza" post="viruses A and B using real-time quantitative PCRJ Clin"/>
  <result pre="Clin Microbiol39200119620011136770 20WHO. WHO information for the molecular detection of" exact="influenza" post="viruses. last accessed 10/2017, &amp;lt;http://www.who.int/influenza/gisrs_laboratory/WHO_information_for_the_molecular_detection_of_influenza_viruses_20171023_Final.pdf&amp;gt;. 21KatingerD.RomanovaJ.FerkoB.FeketeH.EgorovA.Effect of a single"/>
  <result pre="evolutionary genetics analysis version 6.0Mol Biol Evol3020132725272924132122 23AntónA.MarcosM.A.TornerN.Virological surveillance of" exact="influenza" post="and other respiratory viruses during six consecutive seasons from"/>
  <result pre="2006 to 2012 in Catalonia, SpainClin Microbiol Infect225642016e1926363405 24CainiS.SpreeuwenbergP.KusznierzG.F.Distribution of" exact="influenza" post="virus types by age using case-based global surveillance data"/>
  <result pre="25der HeidenM.BuchholzU.Estimation of influenza-attributable medically attended acute respiratory illness by" exact="influenza" post="type/subtype and age, Germany, 2001/02-2014/15Influenza Other Respi Viruses1122017110121 26ModinD.JørgensenM.E.GislasonG.Influenza"/>
  <result pre="timing, and survival: A Danish Nationwide Cohort StudyCirculation2018 27ReedC.ChavesS.S.Daily KirleyP.Estimating" exact="influenza" post="disease burden from population-based surveillance data in the United"/>
  <result pre="between 1997–2007Am J Epidemiol179201415616724190951 29KuoS.-M.ChenG.-W.VeluA.B.Circulating pattern and genomic characteristics of" exact="influenza" post="B viruses in Taiwan from 2003 to 2014J Formos"/>
  <result pre="2014J Formos Med Assoc115201651052227038555 30YasugiM.Kubota-KoketsuR.YamashitaA.Human monoclonal antibodies broadly neutralizing against" exact="influenza" post="B virusPLoS Pathog92013e1003150 31LiuY.TanH.-X.KoutsakosM.Cross-lineage protection by human antibodies binding"/>
  <result pre="B virusPLoS Pathog92013e1003150 31LiuY.TanH.-X.KoutsakosM.Cross-lineage protection by human antibodies binding the" exact="influenza" post="B hemagglutininNat Commun10201932430659197 32PebodyR.WarburtonF.EllisJ.Effectiveness of seasonal influenza vaccine for"/>
  <result pre="antibodies binding the influenza B hemagglutininNat Commun10201932430659197 32PebodyR.WarburtonF.EllisJ.Effectiveness of seasonal" exact="influenza" post="vaccine for adults and children in preventing laboratory-confirmed influenza"/>
  <result pre="seasonal influenza vaccine for adults and children in preventing laboratory-confirmed" exact="influenza" post="in primary care in the United Kingdom: 2015/16 end-of-season"/>
  <result pre="vaccineJ Infect Dis210201412613724446529 34HenryC.PalmA.-K.E.KrammerF.WilsonP.C.From original antigenic sin to the universal" exact="influenza" post="virus vaccineTrends Immunol392018707928867526 35AndrewsS.F.HuangY.KaurK.Immune history profoundly affects broadly protective"/>
  <result pre="broadly protective B cell responses to influenzaSci Transl Med72015316ra192 36GreerA.L.TuiteA.FismanD.N.Age," exact="influenza" post="pandemics and disease dynamicsEpidemiol Infect13820101542154920307340 Appendix A Supplementary material"/>
 </snippets>
</snippetsTree>
